Pipeline of products

NanoValent Pipeline


Bibliography

The following publications, in chronological order, describe the technologies and projects referenced above:

1. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol. 52(7): 1103-11.

2. Llombart-Bosch A, Navarro S. (2001) Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol. 9(3): 255-60.

3. Xu G, Zhang W, Ma MK, McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res. (8): 2605-11.

4. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 65: 8984-9

5. Salvador-Morales, C, Zhang, L, Langer, R, Farokhzad, OC (2009) Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30: 2231–2240.

6. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Critical Reviews in Therapeutic Drug Carrier Systems, 26: 523–580.

7. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, LiuB, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. (2012):126906. PubMed PMID: 23024593; PubMed Central PMCID:PMC3447386.

8. Park, Y., A. C. Luce, R. D. Whitaker, B. Amin, M. Cabodi, R. J. Nap, I. Szleifer, R. O. Cleveland, J. O. Nagy and J. Y. Wong. “Tunable diacetylene polymerized shell microbubbles as ultrasound contrast agents.” Langmuir (2012) 28(8): 3766-72 PubMed PMID:22260537

9. Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, Denny C, Tomlinson JS “An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles” The Journal of surgical research. (2013); 185(1):45-55. PubMed 23827791

10. Kang, H, Shahbazian V, Schafenacker A, Nagy J, Triche T: Development of selective therapy of childhood ALL and Ewing’s sarcoma using targeted hybrid polymerized liposomal nanoparticles (HPLN). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, (2014); Cancer Res 2014; 74 (19 Suppl): Abstract nr 5424.

11. Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K. (2015) CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. Clin Cancer Res. 21(1): 146-56.

12. Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, CruzRE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.Clin Cancer Res. (2015) Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.PubMed PMID: 25733708.

13. Park, Y., T.A. Pham, C. Beigie, M. Cabodi, R.O. Cleveland, J.O Nagy, J. Y. Wong, “Monodisperse Micro-Oil Droplets Stabilized by Polymerizable Phospholipid Coatings as Potential Drug Carriers”, Langmuir (2015), 31, 9762 PubMed PMID: 26303989.

14. Kang, H, Nagy, J Triche, T: Targeted therapy of leukemia and Ewing’s sarcoma by human antibody-targeted nanoparticles. AACR Mini-Symposium: New Molecular Advances in Pediatric Cancer”, AACR Annual Meeting, (2016).

15. Park YC, Zhang C, Kim S, Mohamedi G, Beigie C, Nagy JO, Holt RG, Cleveland RO, Jeon NL, Wong JY. “Microvessels-on-a-Chip to Assess Targeted Ultrasound-Assisted Drug Delivery” ACS applied materials & interfaces. (2016); 8(46):31541-31549 PubMed PMID: 27781429

16. Hyung Gyoo Kang, Jon Nagy and Timothy Triche. Targeted anticancer drug delivery to Ewing’s sarcoma using human anti-CD99 targeted hybrid polymerisation liposomal nanoparticles. Cancer Res. 2018;78 (13 Supplement) 10.1158-7445 AM 2018-3705 .(2018)

17. Catherine A. Gormley, Benjamin J. Keenan, Jo Ann Buczek-Thomas, Amanda C. S. N. Pessoa, Jiang Xu, Fabrice Monti, Patrick Tabeling, R. Glynn Holt, Jon O. Nagy, Joyce Y. Wong. Fibrin-Targeted Polymerized Shell Microbubbles as Potential Theranostic Agents for Surgical Adhesions. Langmuir (2019) DOI: 10.1021/acs.langmuir.8b03692; Volume 35 Issue 31 “Microbubbles: Exploring Gas-Liquid Interfaces for Biomedical Applications.”

18. Hyung Gyoo Kang, Jon Nagy, Sheetal Mitra, Triche Triche. Targeted therapy of Ewing’s sarcoma by human anti CD99 targeted hybrid polymerized liposomal nanoparticles (HPLNs) encapsulating anticancer agents. 2875 / 11; AACR (2019); Session PO.TB08.01 – Targets and Therapies in Pediatric Cancer

19. Sheetal A. Mitra, Namritha Ravinder, Veronica Magnon, Jon Nagy, Timothy J.Triche. Genomic editing of EWS-FLI1 and its targets, and its therapeutic potential in treatment of Ewing sarcoma. 4499 AACR (2019);

20. Hyung Gyoo Kang, Jon O. Nagy, Timothy J. Triche, Bryon Upton, Falguni Dasgupta. Targeted NanoSpheres (TNS): A Novel Therapeutic Platform for Cancer Treatment. Gordon Research Conference. Bridging the Translational Gap in Cancer Nanotechnology.  June (2019)